Kritische 8-K Meldungen
WARNUNG: Kritische 8-K-Meldung(en)
HOCH Abgang Schlüsselpersonen (02.02.2026)
HOCH Abgang Schlüsselpersonen (02.02.2026)
| Datum | Meldung | Schwere | Filing | Auszug |
|---|---|---|---|---|
| 02.02.2026 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | riteria customarily reviewed and assessed. Item 5.02 of this Current Report on Form 8-K below is incorporated into thi |
| 29.12.2025 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | 4(a)(1)(v) of Regulation S-K. Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointmen |
| 25.11.2025 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | the United States federal securities laws. Item 5.02. Departure of Directors or Certain Officers; Election of Director |
| 20.10.2025 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | the Company’s assets (the “Reduction”). Item 5.02. Departure of Directors or Certain Officers; Election of Directors; |
| 02.10.2025 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | ay differ materially from these estimates. Item 5.02. Departure of Directors or Certain Officers; Election of Director |
| 02.09.2025 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; |
| 11.04.2025 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; |
| 12.02.2025 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; |
| 25.09.2024 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; |
Stammdaten
Kala Bio, Inc. is a biopharmaceutical company. It focuses on the development and commercialization of therapeutics using proprietary nanoparticle-based mucus penetrating particles with an initial focus on the treatment of eye diseases. The company was founded by Justin Hanes, Robert S. Langer and Colin R. Gardner in 2009 and is headquartered in Arlington, MA.
Unternehmen & Branche
| Name | KALA BIO, Inc. |
|---|---|
| Ticker | KALA |
| CIK | 0001479419 |
| Boerse | US |
| Sektor | Healthcare |
| Industrie | Biotechnology |
| SIC | 2834 · Pharmaceutical Preparations |
Wertpapier & Kennzahlen
| CUSIP | – |
|---|---|
| ISIN | – |
| Typ | Common Stock |
| Marktkapitalisierung | 2,5 Mio. USD |
| Beta | -1,99 |
| Dividendenrendite | 0,00 % |
Externe Quellen: SEC EDGAR » · FMP-Profil » · Yahoo Finance »
Finanzkennzahlen (SEC XBRL)
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2025-12-31 | 10-K | -26,980,000 | -3.31 | 9,490,000 | 6,996,000 | |
| 2025-09-30 | 10-Q | -7,564,000 | -1.07 | 25,021,000 | -8,665,000 | |
| 2025-06-30 | 10-Q | -11,155,000 | -1.71 | 36,053,000 | -3,206,000 | |
| 2025-03-31 | 10-Q | -8,947,000 | -1.41 | 48,252,000 | 5,708,000 | |
| 2024-12-31 | 10-K | -38,511,000 | -10.15 | 55,483,000 | 12,332,000 | |
| 2024-09-30 | 10-Q | -8,950,000 | -1.93 | 54,079,000 | 6,859,000 | |
| 2024-06-30 | 10-Q | -9,579,000 | -3.16 | 61,606,000 | 13,717,000 | |
| 2024-03-31 | 10-Q | -11,807,000 | -4.20 | 53,033,000 | 6,661,000 | |
| 2023-12-31 | 10-K | -42,199,000 | -17.35 | 55,949,000 | 7,504,000 | |
| 2023-09-30 | 10-Q | -8,704,000 | -3.41 | 61,120,000 | 11,223,000 | |
| 2023-06-30 | 10-Q | -10,413,000 | -4.36 | 66,500,000 | 17,492,000 | |
| 2023-03-31 | 10-Q | -14,455,000 | -6.99 | 72,226,000 | 23,461,000 | |
| 2022-12-31 | 10-K | -44,822,000 | -29.48 | 86,820,000 | 18,974,000 | |
| 2022-09-30 | 10-Q | 29,073,000 | 19.25 | 85,698,000 | -968,000 | |
| 2022-06-30 | 10-Q | -28,111,000 | -18.92 | 84,976,000 | -31,554,000 | |
| 2022-03-31 | 10-Q | -32,941,000 | -22.18 | 111,574,000 | -5,284,000 | |
| 2021-12-31 | 10-K | -142,605,000 | -108.32 | 139,427,000 | 16,804,000 | |
| 2021-09-30 | 10-Q | -28,127,000 | -21.41 | 193,814,000 | 61,469,000 | |
| 2021-06-30 | 10-Q | -36,498,000 | -0.57 | 215,464,000 | 84,270,000 | |
| 2021-03-31 | 10-Q | -30,412,000 | -0.49 | 229,827,000 | 109,792,000 |
Fondsaktivität (Vorquartalsvergleich)
Keine Fondsdaten für dieses Unternehmen vorhanden.
Insider-Transaktionen (12 Monate)
| Datum | Insider | Rolle | Typ | Stückzahl | Kurs | Wert (USD) | Δ | Trend |
|---|---|---|---|---|---|---|---|---|
| 2025-10-23 | Iwicki Mark T | Director | Open Market Sale | -154,894 | 0.81 | -125,464.14 | -170,0% | |
| 2025-10-23 | Reumuth Mary | Officer, CHIEF FINANCIAL OFFICER | Open Market Sale | -967 | 0.82 | -792.94 | -1,1% | |
| 2025-10-22 | Bazemore Todd | Director | Open Market Sale | -47,768 | 0.83 | -39,647.44 | -53,7% | |
| 2025-10-22 | Kharabi Darius | Officer, CHIEF BUSINESS OFFICER | Open Market Sale | -20,806 | 0.83 | -17,268.98 | -23,4% | |
| 2025-10-22 | Reumuth Mary | Officer, CHIEF FINANCIAL OFFICER | Open Market Sale | -32,230 | 0.83 | -26,750.90 | -36,3% | |
| 2025-10-22 | Brazzell Romulus K | Officer, SEE REMARKS | Open Market Sale | -46,748 | 0.83 | -38,800.84 | -52,6% | |
| 2025-10-01 | BAKER BROS. ADVISORS LP | Open Market Sale | -50,640 | 1.38 | -70,075.63 | -95,0% | ||
| 2025-10-01 | BAKER BROS. ADVISORS LP | Open Market Sale | -462,967 | 1.38 | -640,653.73 | -868,2% | ||
| 2025-09-30 | BAKER BROS. ADVISORS LP | Open Market Sale | -195,425 | 1.60 | -311,878.76 | -422,7% | ||
| 2025-09-30 | BAKER BROS. ADVISORS LP | Open Market Sale | -21,376 | 1.60 | -34,113.96 | -46,2% | ||
| 2025-06-24 | Brazzell Romulus K | Officer, SEE REMARKS | Open Market Sale | -5,251 | 4.01 | -21,056.51 | -28,5% | |
| 2025-06-24 | Kharabi Darius | Officer, CHIEF BUSINESS OFFICER | Open Market Sale | -4,511 | 4.01 | -18,089.11 | -24,5% | |
| 2025-06-24 | Iwicki Mark T | Director | Open Market Sale | -13,227 | 4.01 | -53,040.27 | -71,9% | |
| 2025-06-24 | Bazemore Todd | Officer, SEE REMARKS | Open Market Sale | -4,058 | 4.01 | -16,272.58 | -22,1% | |
| 2025-06-24 | Reumuth Mary | Officer, CHIEF FINANCIAL OFFICER | Open Market Sale | -3,631 | 4.01 | -14,560.31 | -19,7% | |
| 2025-06-03 | Kharabi Darius | Officer, CHIEF BUSINESS OFFICER | Open Market Sale | -730 | 3.74 | -2,730.20 | -3,7% | |
| 2025-06-03 | Iwicki Mark T | Director | Open Market Sale | -10,866 | 3.74 | -40,638.84 | -55,1% | |
| 2025-06-03 | Brazzell Romulus K | Officer, SEE REMARKS | Open Market Sale | -3,687 | 3.74 | -13,789.38 | -18,7% | |
| 2025-06-03 | Reumuth Mary | Officer, CHIEF FINANCIAL OFFICER | Open Market Sale | -2,850 | 3.74 | -10,659.00 | -14,4% | |
| 2025-06-03 | Bazemore Todd | Officer, SEE REMARKS | Open Market Sale | -3,390 | 3.74 | -12,678.60 | -17,2% | |
| 2025-06-03 | Iwicki Mark T | Director | Open Market Sale | -10,866 | 3.74 | -40,638.84 | -55,1% |
Top-Fondshalter
Keine Fondsdaten zu dieser Aktie vorhanden.